Amgen's shares are near their yearly high after strong third-quarter earnings and a raised forecast for 2026.

Nov 4, 2026, 12:50 PM ETResultsRead the original at Benzinga

Good for AMGN

Amgen beat third-quarter profit and sales expectations and raised its 2026 forecasts, supporting a stronger business outlook. Its obesity-drug data will not arrive until 2027, but the reported results and higher forecasts carry more weight.

AMGN · Amgen Inc.

AI read · Good for AMGN

The AI's read

The higher company forecast suggests Amgen expects sales and profit to keep growing. Growth across 17 medicines adds support beyond one product. More MariTide data will not arrive until 2027, leaving its role in obesity care uncertain. The strong quarter and raised forecast carry more weight.

Get alerts for AMGN

Follow Amgen Inc. (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AMGN

Free on the App Store and Google Play, or on the web.